Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells

Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells

Abstract Background The treatment of high‐risk B‐cell lymphoma (BCL) remains a challenge, especially in the elderly. Methods A total of 83 patients (median age 65 years), who have achieved a complete response after induction therapy, were divided into two groups: R2 + GM‐CSF regimen (lenalidomide, r...

Full description

Bibliographic Details
Main Authors: Shunrong Sun, Wulipan Fulati, Lin Shen, Min Wu, Zilan Huang, Wensi Qian, Pingping Chen, Yingwei Hu, Mingyue Chen, Yu Xu, Hongdi Zhang, Jiexian Ma, Yanhui Xie
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Cancer Medicine
Subjects:
B‐cell lymphoma
lenalidomide
maintenance therapy
rhGM‐CSF
rituximab
Online Access:https://doi.org/10.1002/cam4.5969

Internet

https://doi.org/10.1002/cam4.5969

Similar Items